Canakinumab Cuts Secondary CV Events in Phase 3 CANTOS Canakinumab Cuts Secondary CV Events in Phase 3 CANTOS

Top-line results show the monoclonal antibody, given on top of standard care, significantly reduced the risk of cardiovascular death, nonfatal MI, and nonfatal stroke in patients with a prior MI and elevated CRP.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news